Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
135
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis